Showing 2781-2790 of 4166 results for "".
- Ocular Therapeutix Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Diseasehttps://modernod.com/news/ocular-therapeutix-announces-topline-results-for-phase-2-clinical-trial-of-otx-ded-for-the-short-term-treatment-of-dry-eye-disease/2480496/Ocular Therapeutix announced positive topline results from its phase 2 clinical trial of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of dry eye disease. The phase 2 clinical trial is a US-based, randomized, double-masked, vehicle-controlled, m
- Avisi Technologies Announces Positive 12-Month Clinical Data on VisiPlate Aqueous Shunthttps://modernod.com/news/avisi-technologies-announces-positive-12-month-clinical-data-on-visiplate-aqueous-shunt/2484305/Avisi Technologies announced positive 12-month clinical data on its VisiPlate Aqueous Shunt from the VITA trial during the 2025 AAO Annual Meeting. The study was presented by Jonathan Myers, MD, chief of the glaucoma service at Wills Eye Hospital, Thomas Jefferson University, in Philadelphia.
- AAVantgarde Bio Presents Clinical Data from LUCE-1 Gene Therapy Trial in Usher Syndrome Type 1Bhttps://modernod.com/news/aavantgarde-bio-presents-clinical-data-from-luce-1-gene-therapy-trial-in-usher-syndrome-type-1b/2484135/AAVantgarde Bio announced updated clinical results from its ongoing LUCE-1 phase 1/2 study of AAVB-081, presented at the 25th European Society of Retina Specialists (EURETINA) annual congress in Paris. The LUCE-1 study
- PolyActiva Initiates US Phase 2b Clinical Trial of PA5108 Biodegradable Ocular Implant for Glaucoma and OHThttps://modernod.com/news/polyactiva-enrolls-first-patient-in-us-phase-2b-clinical-trial-of-its-ocular-micro-implant-for-glaucoma-and-ocular-hypertension/2482925/PolyActiva announced the enrollment of the first US patient in its phase 2b clinical trial evaluating PA5108, a novel intracameral, biodegradable micro implant designed to provide sustained IOP reduction in patients with primary open-angle glaucoma (POAG)
- AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into Phase 1/2 Clinical Trialhttps://modernod.com/news/aavantgarde-receives-fda-clearance-to-progress-stargardt-disease-asset-aavb-039-into-phase-12-clinical-trial/2482885/AAVantgarde Bio announced that the FDA has cleared its investigational new drug (IND) application for AAVB-039, the company’s gene therapy program for Stargardt disease. AAVantgarde is now initiating CELESTE, a first-in-human phase 1/2 clinical trial in the United States to e
- Feliqs Secures $9 Million Series A to Advance FLQ-101 Clinical Trial for Retinopathy of Prematurityhttps://modernod.com/news/feliqs-secures-9-million-series-a-to-advance-flq-101-clinical-trial-for-retinopathy-of-prematurity/2482869/Feliqs Corp. announced the successful completion of a $9 million Series A financing round to advance the company's lead investigational therapy, FLQ-101, into clinical development. Designed as a once-daily oral or intravenous formulation, FLQ-101 aims
- Qlaris Bio to Present New Clinical and Preclinical Data on QLS-111 at 2025 World Glaucoma Congresshttps://modernod.com/news/qlaris-bio-to-present-new-clinical-and-preclinical-data-on-qls-111-at-2025-world-glaucoma-congress/2482859/Qlaris Bio announced that new data from studies of its lead investigational compound QLS-111 will be presented at the 2025 World Glaucoma Congress (WGC). This will include an oral presentation on clinical data from the recently completed QC-111-201 “Osprey” and QC-111-203 “
- Atsena Therapeutics Announces Positive Clinical Data for Gene Therapy to Treat X-linked Retinoschisis (XLRS)https://modernod.com/news/atsena-therapeutics-announces-positive-clinical-data-for-gene-therapy-to-treat-x-linked-retinoschisis-xlrs/2482808/Atsena Therapeutics announced interim data from Part A of its phase 1/2 LIGHTHOUSE clinical trial evaluating ATSN-201 for the treatment of X-linked retinoschisis (XLRS). The study demonstrated a favorable safety profile and compelling signs of efficacy in adul
- First Patients Enrolled in 4DMT's Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMDhttps://modernod.com/news/first-patients-enrolled-in-4dmts-phase-3-clinical-trial-evaluating-4d-150-in-wet-amd/2482694/4D Molecular Therapeutics (4DMT) announced that the first patients have been enrolled across multiple sites in the 4FRONT-1 phase 3 clinical trial evaluating 4D-150 for the treatment of wet age-related macular degeneration (AMD). "This is a historic moment for 4DMT as we becom
- Seonix Bio Launches SightScore, the First Clinical Polygenic Risk Score Test for Glaucoma in the UShttps://modernod.com/news/seonix-bio-launches-sightscore-the-first-clinical-polygenic-risk-score-test-for-glaucoma-in-the-us/2482672/Seonix Bio announced the US launch of SightScore, which the company descibes as the first commercially available clinical polygenic risk score testing service for primary open-angle glaucoma. Already available in Australia and New Zealand, SightScore utilizes